

Accepted Manuscript


Pharmacological Management of Nonalcoholic Fatty Liver Disease

Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi

PII: S0026-0495(16)30008-7
DOI: doi: [10.1016/j.metabol.2016.04.004](https://doi.org/10.1016/j.metabol.2016.04.004)
Reference: YMETA 53407

To appear in: *Metabolism*

Received date: 30 March 2016
Revised date: 16 April 2016
Accepted date: 18 April 2016



Please cite this article as: Barb Diana, Portillo-Sanchez Paola, Cusi Kenneth, Pharmacological Management of Nonalcoholic Fatty Liver Disease, *Metabolism* (2016), doi: [10.1016/j.metabol.2016.04.004](https://doi.org/10.1016/j.metabol.2016.04.004)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Pharmacological Management of Nonalcoholic Fatty Liver DiseaseDiana Barb^{1,2}, Paola Portillo-Sanchez^{1,2} and Kenneth Cusi^{1,2}

¹Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, Gainesville, FL and ²Division of Endocrinology, Diabetes, and Metabolism at Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida

Correspondence to:

Kenneth Cusi, M.D., F.A.C.P., F.A.C.E

Professor of Medicine, Chief, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, Gainesville, FL

Phone: 352-273-8662

Email: Kenneth.Cusi@medicine.ufl.edu

Address: 1600 SW Archer Road, room H-2. Gainesville, Florida 32610**Keywords:** obesity, Nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), metformin, thiazolinediones, PPAR γ , pioglitazone, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), liraglutide, sodium-glucose co-transporter 2 (SGLT2) inhibitors.**Figures: 1 Tables: 2****Word count:** 5,188**References:** 152

Download English Version:

<https://daneshyari.com/en/article/5903003>

Download Persian Version:

<https://daneshyari.com/article/5903003>

[Daneshyari.com](https://daneshyari.com)